Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase NA 8Phase 3 3Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 2Completed 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Locally Advanced Lung Carcinoma 1Advanced Cancer 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Radiation Dose Hypofractionation × Clear all
NCT04951063 2023-12-15

Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC

Sun Yat-sen University

Phase 1 Completed
18 enrolled

Locally Advanced Lung Carcinoma

NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡